中国广泛期小细胞肺癌一线化疗添加Durvalumab的成本效果分析数据集

数据集获取（Figshare）

• 源站标题：Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
• DOI：10.6084/m9.figshare.14113189.v1
• 发布日期：2021-02-25
• 文件数：2 个
• 文件总体积：291.90 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-effectiveness_of_adding_durvalumab_to_first-line_chemotherapy_for_extensive-stage_small-cell_lung_cancer_in_China/14113189

命令行下载

curl -L -o "ierp_a_1888717_sm9657.docx" "https://ndownloader.figshare.com/files/26615695"
curl -L -o "ierp_a_1888717_sm9656.docx" "https://ndownloader.figshare.com/files/26615698"

文件清单

• ierp_a_1888717_sm9657.docx（16.89 KB）
• ierp_a_1888717_sm9656.docx（275.01 KB）

文件总体积 291.90 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Durvalumab plus chemotherapy could significantly improve overall survival compared with chemotherapy alone in the first-line treatment of extensive-stage small-cell lung cancer (SCLC). However, its long-term economic outcomes remain unclear yet. This study aimed to evaluate the cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage SCLC from the perspective of the Chinese health-care system.
A decision-analytic model with 10-year horizon was developed to estimate the health and economic outcomes of adding durvalumab to first-line treatment for extensive-stage SCLC. The primary outcomes included total costs, life years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). Costs and utility values were obtained from the published literature. A scenario analysis for a patient assistance program (PAP) was conducted. Sensitivity analyses were performed to explore the robustness of the model outcomes.
Durvalumab plus chemotherapy yielded additional 0.25 QALYs, with incremental costs of 76,354 USD, resulting in an ICER of 302,051 USD/QALY compared with chemotherapy alone, when PAP was available, the ICER was 192,591 USD/QALY. Sensitivity analyses confirmed the robustness of model outcomes.
Adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer is unlikely to be cost-effectiveness in China.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.14113189.v1（source: https://tandf.figshare.com/articles/dataset/Cost-effectiveness_of_adding_durvalumab_to_first-line_chemotherapy_for_extensive-stage_small-cell_lung_cancer_in_China/14113189）。